Tamoxifen Ameliorates Cholestatic Liver Fibrosis in Mice: Upregulation of TGFβ and IL6 Is a Potential Protective Mechanism

Tamoxifen Ameliorates Cholestatic Liver Fibrosis in Mice: Upregulation of TGFβ and IL6 Is a Potential Protective Mechanism

The available treatments for cholestatic liver fibrosis are limited, and the disease often progresses to liver cirrhosis. Tamoxifen is a selective modulator of estrogen receptors, commonly used in breast cancer therapy. A recent in vitro study showed that tamoxifen deactivates hepatic stellate cells...

Full description

Bibliographic Details
Main Authors: Dino Šisl, Darja Flegar, Maša Filipović, Petra Turčić, Pavao Planinić, Alan Šućur, Nataša Kovačić, Danka Grčević, Tomislav Kelava
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Biomedicines
Subjects:
liver fibrosis
tamoxifen
DDC model
cholestatic liver disease
Online Access:https://www.mdpi.com/2227-9059/10/5/1209

Similar Items

Similar Items